Eagle Pharmaceuticals Inc (EGRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has a cash flow conversion efficiency ratio of 0.000x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-126.00K) by net assets ($252.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eagle Pharmaceuticals Inc (EGRX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Eagle Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eagle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harris Technology Group Ltd
AU:HT8
|
-0.192x |
|
Marvel Discovery Corp
V:MARV
|
0.000x |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
-0.005x |
|
Addentax Group Corp
NASDAQ:ATXG
|
-0.005x |
|
NuGen Medical Devices Inc
V:NGMD
|
0.072x |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
-0.786x |
|
Tree House Education & Accessories Limited
NSE:TREEHOUSE
|
0.000x |
|
Pembroke VCT PLC
LSE:PEMB
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual cash flow conversion efficiency of Eagle Pharmaceuticals Inc from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see Eagle Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $233.56 Million | $30.80 Million | 0.132x | -17.55% |
| 2021-12-31 | $176.45 Million | $28.22 Million | 0.160x | -39.90% |
| 2020-12-31 | $186.01 Million | $49.50 Million | 0.266x | -14.84% |
| 2019-12-31 | $179.17 Million | $55.99 Million | 0.312x | -4.11% |
| 2018-12-31 | $160.76 Million | $52.38 Million | 0.326x | -0.93% |
| 2017-12-31 | $179.14 Million | $58.92 Million | 0.329x | -6.52% |
| 2016-12-31 | $151.23 Million | $53.21 Million | 0.352x | +427.08% |
| 2015-12-31 | $90.34 Million | $-9.72 Million | -0.108x | +74.28% |
| 2014-12-31 | $33.10 Million | $-13.84 Million | -0.418x | +85.39% |
| 2013-12-31 | $2.05 Million | $-5.88 Million | -2.863x | -322.75% |
| 2012-12-31 | $-12.10 Million | $-15.55 Million | 1.285x | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more